Automata raises $50M for all times sciences automation

Automata raises M for all times sciences automation

[ad_1]

Hearken to this text

Voiced by Amazon Polly
Automata raises M for all times sciences automation

Automata’s collaborative robotic arm Eva. | Supply: Automata

Automata, an organization centered on life sciences automation, raised $50 million in Sequence B funding. The corporate plans to make use of the financing to additional develop its lab automation platform, Automata Labs, to be used in and out of doors of the UK.

Automata Labs was created to make scaling up straightforward for diagnostics labs, drug discovery labs and extra. The corporate claims its system may be carried out inside weeks and might automate every stage of workflow. It additionally presents a versatile robotic arm referred to as Eva. Eva has six levels of freedom and was designed to work on exact and repeatable duties. It has a lower than 3 lb payload (1.25 kg). 

Octopus Ventures led the financing spherical. Current traders, like Hummingbird, Latitude Ventures, ABB Know-how Ventures and Osomer Capital additionally participated. The spherical additionally included strategic traders, like In-Q-Tel. 

“Automata Labs accelerates human ingenuity, empowering labs and scientists to realize constant outcomes sooner, on a larger scale, and to in the end upscale their ambitions,” Jess McCreadie, principal at Octopus Ventures, stated. “We’re delighted to have led this financing spherical as Automata represented precisely the kind of extremely modern firm we put money into and assist. We’re excited for Automata’s subsequent steps, each throughout the life sciences business, and past.”

Automata started in 2015, and it was based by Mostafa ElSayed and Suryansh Chandra, two architects from Zaha Hadid’s analysis lab. The corporate’s objective is to allow new alternatives for innovation with automation. 

“For a lot too lengthy scientists and clinicians have been having to work with overly complicated lab options whereby the gear and software program are disjointed and tough to orchestrate,” ElSayed, now the corporate’s CEO, stated. “Options are additionally typically too inflexible and inappropriate for labs with small geographic footprints. Our subsequent era know-how solves this.”

Up to now, the corporate has raised a complete of $59.5 million in financing. The corporate is predicated in London. 

[ad_2]

Previous Article

Ukraine is popping to on-line crypto crowdfunding

Next Article

Ultrasensitive, New Design to SARS-CoV-2 Antigen Check

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *

Subscribe to our Newsletter

Subscribe to our email newsletter to get the latest posts delivered right to your email.
Pure inspiration, zero spam ✨